Matinas BioPharma Investor Presentation Deck

14 High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA) Invasive aspergillosis (IA) is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients with hematological malignancies and transplant recipients ~15,000 new cases per year in the U.S. alone WHO, CDC, and FDA consider IA a critical priority and a global public health concern • IDSA Guidelines recommend treatment with mold-active azoles as first-line treatment for 6-12 weeks ● ● Azole use requires significant expertise to manage toxicities and significant drug-drug interactions that often limits duration of use Resistance to azoles has been increasing globally Recently, cases of breakthrough IA have been reported in patients receiving antifungal prophylaxis Failures attributed to non-compliance, poor absorption, DDIs, or infection with a drug-resistant Aspergillus species Patients suffering from IA with little or no treatment options among the highest unmet medical need with approximately 3,000-5,000 cases per year (U.S. only) Rare disease/orphan commercial opportunity I * Phase 3 trial dependent on securing partnership(s) or non-dilutive government funds COPYRIGHT MATINAS BIOPHARMA 2024 MATINAS BIOPHARMA

View entire presentation